Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA)
Canaccord Genuity Group has initiated coverage on Tyra Biosciences (NASDAQ:TYRA) with a "buy" rating and a $50 price target, suggesting a potential upside of 26.23%. This new rating aligns with a "Moderate Buy" consensus from other analysts, with an average target price of $45.43. The company recently reported a quarterly EPS loss of $0.57, missing estimates, while its stock currently trades around $39.61.
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target
Canaccord Genuity has initiated coverage on Tyra Biosciences (TYRA) with a "Buy" rating and a price target of $50. This positive analyst recommendation follows several other firms, including Wedbush, Oppenheimer, and Barclays, also raising price targets or initiating coverage on the biotechnology company in recent months. Tyra Biosciences is focused on developing precision medicines for Fibroblast Growth Factor Receptor (FGFR) biology, with lead product candidate TYRA-300 in Phase 1 clinical study.
CCORF Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $50
CCORF analyst John Newman has initiated coverage on TYRA BIOSCIENCES, INC. (TYRA.US) with a 'buy' rating and set a target price of $50. According to TipRanks, Newman has a 38.6% success rate and a 0.7% average return over the past year. This information is intended for educational purposes and is not investment advice.
Tyra Biosciences names Julia Rueb principal accounting officer, succeeding Alan Fuhrman
Tyra Biosciences has appointed Julia Rueb as its new principal accounting officer, effective April 1, 2026, replacing Alan Fuhrman. Rueb, who has been VP of Finance since January 2024, will continue in her role while Fuhrman remains Chief Financial Officer. The company filed an 8-K form with the SEC regarding these changes.
Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer
Tyra Biosciences has appointed Julia Rueb, previously Vice President of Finance, as its principal accounting officer, effective April 1, 2026. She succeeds Alan Fuhrman in this specific role, though he will continue to serve as the company’s chief financial officer and principal financial officer. Rueb brings extensive experience from previous senior accounting roles at Tyra and audit experience from Ernst & Young, primarily serving public life sciences companies.
Tyra Biosciences (TYRA) VP details multi-year stock option grants
Tyra Biosciences' Vice President of Finance, Yuliya Rueb, has filed an initial insider report detailing her existing stock option holdings. The filing outlines multiple option grants to purchase common stock, with exercise prices between $6.50 and $21.57 per share and expiration dates ranging from 2032 to 2035. These options vest over time, contingent on her continuous service to the company.
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59
Barclays analyst Eliana Merle has reiterated a Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US), maintaining the target price at $59. According to TipRanks data, the analyst has a 39.7% success rate and a 3.1% average return over the past year. This report highlights the analyst's continued positive outlook on the company.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Ten analysts have given Tyra Biosciences (NASDAQ:TYRA) a "Moderate Buy" consensus rating, with an average 1-year price target of $44.67. Several brokerages recently initiated or raised coverage, including Piper Sandler with a $56 target and HC Wainwright with a $45 target. Despite a director's sale of shares, institutional ownership remains high at 84.14%, with firms like Commodore Capital and Farallon increasing their stakes, though the company reported a quarterly EPS miss of ($0.57) against estimates of ($0.54).
Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones
This article provides a quantitative analysis of Tyra Biosciences Inc. (TYRA), highlighting strong sentiment across all horizons supportive of an overweight bias despite elevated downside risk. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, detailing support and resistance levels for near-term, mid-term, and long-term horizons, and encourages users to access real-time signals and personalized alerts.
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year High - What's Next?
Tyra Biosciences (NASDAQ:TYRA) hit a new 52-week high of $40.65, backed by a "Moderate Buy" consensus rating and an average price target of $44.67 from analysts. Despite this, the company remains unprofitable, missing its last quarterly EPS estimate, and a director recently sold a significant number of shares. Institutional investors hold approximately 84% of the stock.
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Tyra Biosciences has seen a significant share price increase over the last year, demonstrating strong growth plans. The company has a cash runway of approximately 2.7 years from December 2025, with cash reserves of US$256m against an annual cash burn of US$95m. Despite an increase in cash burn, which indicates investment in future growth, its low cash burn relative to its market capitalization suggests it can easily raise additional funds if needed.
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation
Wedbush has reiterated its "outperform" recommendation for Tyra Biosciences (TYRA). The specific reasons or updated price target for this rating were not detailed in the provided content.
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation
Wedbush has reiterated its "outperform" rating for Tyra Biosciences (TYRA). The firm's analyst, Robert Driscoll, stated that despite challenges such as a stock offering reducing the company's valuation, Tyra's strong financial position and ongoing progress in its oncology pipeline remain positive indicators. The company is advancing TYRA-200 for FGFR3+ cancers and plans for 2024 include submitting an IND for TYRA-300 in achondroplasia.
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock
Tyra Biosciences (NASDAQ:TYRA) Director Gilla Kaplan sold 14,295 shares of the company's stock for $528,486.15 on March 25th, reducing her stake by 33.61%. The company's stock opened at $36.29 with a market cap of $1.95 billion, and analysts project an EPS of -$1.57 for the current fiscal year. Despite the sale, institutional investors have recently increased their positions, and the stock holds a "Moderate Buy" consensus rating from analysts with an average target price of $44.67.
Tyra Biosciences director Kaplan sells shares worth $528k
Gilla Kaplan, a director at Tyra Biosciences, sold shares totaling $528,506 and $2,007,152 on March 25 and March 26, 2026, respectively, while also exercising options to acquire shares. These sales occurred as TYRA's stock trades near its 52-week high after a significant surge. Analysts maintain a "Strong Buy" consensus, and the company recently announced a $126 million stock sale to support development efforts, reflecting continued confidence in its therapeutic innovations.
Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares
Tyra Biosciences director Gilla Kaplan exercised stock options for a total of 67,467 shares on March 25-26, 2026, at an exercise price of $2.25 per share. Kaplan subsequently sold 14,295 shares in open-market transactions at a weighted average price of $36.9714 and disposed of 53,172 shares back to the issuer at $37.7483. After these transactions, Kaplan directly holds 28,231 shares of Tyra Biosciences common stock.
Insider plans sale of 53,172 TYRA shares via option exercise (TYRA)
A recent SEC Form 144 filing indicates a proposed sale of 53,172 common shares of Tyra Biosciences, Inc. (TYRA) through a stock option exercise for cash to the issuer on March 26, 2026. The filing also notes Gilla Kaplan sold 14,295 shares on March 25, 2026. This is a routine insider disclosure regarding planned transactions.
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma
DelveInsight's report indicates a significant expansion in the Non-Muscle Invasive Bladder Cancer (NMIBC) pipeline, with over 20 pharmaceutical companies developing more than 22 pipeline therapies. Key players include CG Oncology, Janssen, Tyra Biosciences, and UroGen Pharma, with promising therapies like Cretostimogene grenadenorepvec, TAR-210, TYRA-300, and UGN-301 in various stages of clinical development. The report also highlights the recent FDA approval of Ferring Pharmaceuticals' ADSTILADRIN for high-risk, BCG-unresponsive NMIBC, underscoring advancements in treatment options.
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma
DelveInsight's "Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2026" report reveals that over 20 pharmaceutical companies are actively developing more than 22 pipeline therapies for Non-Muscle Invasive Bladder Cancer (NMIBC). Key players include CG Oncology, Janssen, Tyra Biosciences, and UroGen Pharma, with drugs like Cretostimogene grenadenorepvec, TAR-210, TYRA-300, and UGN-301 in various stages of clinical development. The report highlights significant advancements, such as the recent FDA label update for Ferring Pharmaceuticals' ADSTILADRIN, and discusses the mechanisms of action for promising emerging therapies.
[144] Tyra Biosciences, Inc. SEC Filing
This article reports on Tyra Biosciences, Inc.'s SEC Form 144 filing, detailing a proposed sale of securities. The filing indicates a neutral impact and sentiment, outlining the sale of 14,295 common shares with an aggregate market value of $528,506.16 through Morgan Stanley Smith Barney LLC, acquired via stock option exercise on March 25, 2026. The article also provides an overview of TYRA's stock data, recent news, and other SEC filings.
Dabo gratinib designation honors key Tyra Biosciences executives
Tyra Biosciences has named its tyrosine kinase inhibitor "Dabo gratinib" to honor two key executives, Daniel Bensen and Robert L. Hudkins, recognizing their foundational roles in the company. The compound is designed as an oncology treatment, aligning with Tyra Biosciences' focus on targeted therapies. The company has also recently presented research on FGFR3-selective inhibition and strengthened collaborations in urologic oncology.
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance
Tyra Biosciences (TYRA) has experienced significant share price growth over the past year, up 247.5%, despite a recent 2.7% decline. The company currently trades at a Price-to-Book (P/B) ratio of 7.7x, which is considerably higher than the industry and peer averages, suggesting it may be overvalued, especially given its lack of current revenue and clinical trial uncertainties. Despite trading below the average analyst target price, investors are advised to carefully review underlying data and consider both strengths and warning signs before making investment decisions.
Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook
Boone Capital Management has significantly invested in Tyra Biosciences, which is currently advancing multiple clinical trials focused on FGFR3 biology. This investment signals growing institutional interest in Tyra Biosciences, which has seen substantial share price momentum, including a 247.5% return over the past year. Investors are advised to watch trial timelines, data readouts, and cash burn as the company reports no revenue and is currently unprofitable.
Technical Reactions to TYRA Trends in Macro Strategies
This article provides a technical analysis of Tyra Biosciences Inc. (NASDAQ: TYRA) as of March 22, 2026. It highlights strong sentiment across all trading horizons supporting an overweight bias, despite elevated downside risk due to a lack of additional long-term support signals. The report also outlines three AI-generated institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels for different risk profiles.
Cantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendation
Cantor Fitzgerald has initiated coverage on Tyra Biosciences (TYRA) with an "Overweight" rating. This endorsement from a reputable financial firm suggests a positive outlook on the company's stock performance. Investors will likely be watching how the market reacts to this new recommendation.
Boone Capital Invests in Tyra Biosciences: $10.48M Stake Acquired - News and Statistics
Boone Capital Management has acquired a significant stake in Tyra Biosciences, a biopharmaceutical company specializing in targeted cancer treatments. The investment firm purchased 398,482 shares valued at $10.48 million, representing 3.3% of its reported assets under management. Tyra Biosciences' stock has seen substantial growth over the past year, and the company maintains sufficient financial resources for its future operations.
Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price
Piper Sandler has increased its price target for Tyra Biosciences (NASDAQ:TYRA) to $56 from $42, maintaining an "overweight" rating and suggesting a 44.8% upside. Despite a recent EPS miss, the stock is trading up, with institutional investors holding a significant portion of shares. Analyst opinions are varied, but the consensus on MarketBeat remains a "Moderate Buy" with an average target price of $44.67.
Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $56
Piper Sandler has reiterated a Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US), with analyst Allison Bratzel increasing the target price from $42 to $56. Bratzel has a strong track record, boasting a 58.7% success rate and an average return of 47.3% over the past year according to TipRanks data. This adjustment reflects continued confidence in the company's prospects.
Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Thursday
Tyra Biosciences (TYRA) is anticipated to release its Q4 2025 earnings before market open on Thursday, March 26th, with analysts projecting a loss of ($0.54) per share. The company previously missed estimates, reporting a ($0.57) loss per share. Shares are currently trading at $38.05, and analysts hold a "Moderate Buy" consensus rating with an average target price of $42.33.
Tyra Biosciences (TYRA) CFO adds 1,376 shares via employee stock plan
Tyra Biosciences CFO Alan Fuhrman acquired 1,376 shares of common stock at $9.129 per share through the company's 2021 Employee Stock Purchase Plan on March 13, 2026. This transaction increased his direct holdings to 16,164 common shares and is noted as a routine, compensation-related acquisition rather than an open-market purchase. The Form 4 filing details the change in beneficial ownership.
Tyra Biosciences (TYRA) CEO adds 1,463 ESPP shares, holdings reach 1.36M
Tyra Biosciences President and CEO Harris Todd acquired 1,463 common shares at $9.129 per share through the company's 2021 Employee Stock Purchase Plan on March 13, 2026. This transaction increased his direct holdings to 1,358,631 shares. The acquisition was a compensation-related grant and not an open-market purchase, representing a minor addition to his existing ownership.
Tyra Biosciences, Inc. $TYRA Shares Acquired by HighVista Strategies LLC
HighVista Strategies LLC significantly increased its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 163.6% in the third quarter, now owning 65,812 shares valued at $921,000. Other institutional investors like Millennium Management LLC and Goldman Sachs Group Inc. also adjusted their positions. Meanwhile, a director sold a substantial amount of shares, and analysts have issued a range of ratings with a consensus price target of $42.33.
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year High - Time to Buy?
Tyra Biosciences (NASDAQ:TYRA) recently hit a new 52-week high, with shares trading as high as $37.84. Analyst sentiment is generally positive, with a consensus "Moderate Buy" rating and a price target of $42.33, despite the company reporting negative earnings. The article also notes significant institutional ownership and recent insider selling activity.
Boothbay Fund Management LLC Makes New $2.61 Million Investment in Tyra Biosciences, Inc. $TYRA
Boothbay Fund Management LLC has made a new $2.61 million investment in Tyra Biosciences, Inc. (NASDAQ:TYRA), acquiring 186,670 shares. This move is part of a broader trend of institutional investors increasing their stakes, bringing their total ownership to 84.14%. Despite some analyst downgrades and a recent EPS miss, the stock holds a "Moderate Buy" consensus rating with a price target of $42.33.
Tyra Biosciences, Inc. $TYRA Shares Purchased by Commodore Capital LP
Commodore Capital LP increased its stake in Tyra Biosciences (NASDAQ:TYRA) by 8.9% in Q3, now holding 3,375,000 shares valued at $47.22 million, making it their 17th largest holding. Other institutional investors like Caligan Partners LP and Balyasny Asset Management L.P. also significantly boosted their positions. Despite a consensus "Moderate Buy" rating from analysts with a target price of $42.33, the company recently missed quarterly EPS estimates and has a market capitalization of $1.95 billion.
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation
Wedbush has reiterated its Outperform rating for Tyra Biosciences (TYRA). This continued recommendation indicates the firm's positive outlook on the company's stock performance. The article does not provide further details on the rationale behind this rating.
Tyra Biosciences stock hits all-time high at 36.69 USD
Tyra Biosciences' stock has reached an all-time high of $36.69, marking a significant 235% increase over the past year and raising its market capitalization to $1.94 billion. Despite appearing overvalued by some analyses, the company recently secured $126 million from a stock sale and has received positive analyst ratings with price targets as high as $55-$59.62, driven by advancements in its drug dabogratinib.
ACMG meeting attendance advances FGFR3 inhibition work, Tyra Biosciences outlines
Tyra Biosciences is attending the ACMG 2026 Annual Clinical Genetics Meeting in Baltimore to discuss its latest developments in FGFR3-selective inhibition. The company aims to engage with industry professionals and highlight its ongoing innovation in clinical genetics. Attendees are invited to connect with Tyra Biosciences' team at their event booth to learn more.
Tyra Biosciences (NASDAQ:TYRA) Sets New 12-Month High - Here's What Happened
Tyra Biosciences (NASDAQ:TYRA) reached a new 52-week high of $36.20, driven by broadly positive analyst sentiment including a raised price target from HC Wainwright and new "overweight" ratings from Barclays, Cantor Fitzgerald, and William Blair. Despite missing its last quarterly EPS estimate and remaining unprofitable, the company has a consensus "Moderate Buy" rating and a target price of $42.33. Insider selling activity was noted, though institutional investors have increased their holdings, with 84.14% of the stock owned by hedge funds and institutional investors.
Trading the Move, Not the Narrative: (TYRA) Edition
This article provides an AI-generated analysis for Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting strong sentiment across all horizons and presenting three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It details entry zones, targets, and stop losses for each strategy, along with multi-timeframe signal analysis, to help traders manage risk and optimize positions with a bias towards overweight.
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating
TD Cowen analyst Tyler Van Buren has reiterated a Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US). According to TipRanks data, Van Buren has a 55.6% success rate and a 23.1% average return over the past year. This rating is based on independent third-party analysis provided by TipRanks, which tracks financial analysts' recommendations and performance.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Brokerages
Tyra Biosciences (NASDAQ:TYRA) has received an average "Moderate Buy" rating from brokerages, with an average 12-month target price of $42.3333. This rating is based on recommendations from ten analysts, with eight "buy," one "strong buy," and one "sell" rating. Recent analyst actions include price target increases and new coverage with "buy" or "overweight" ratings, despite the company missing its most recent quarterly EPS estimate.
Assessing Tyra Biosciences (TYRA) Valuation After William Blair Coverage And Dabogratinib Progress
Tyra Biosciences (TYRA) has gained investor attention following William Blair's coverage, progress with its drug candidate dabogratinib, a new Phase 2 trial, and executive appointments. The company's stock has seen strong returns of 85.57% over 90 days and 138.29% over one year, trading at a price-to-book ratio of 5.6x. While this is lower than direct peers, it's higher than the broader US Biotechs industry, suggesting that the market anticipates significant future growth despite the company's current net loss.
HC Wainwright Boosts Earnings Estimates for Tyra Biosciences
HC Wainwright has increased its Q2 2026 EPS estimate for Tyra Biosciences to ($0.65) from ($0.66) and maintained a "Buy" rating with a $45 price target, despite the company missing Q1 EPS estimates. The firm also provided updated earnings forecasts for Q3, Q4, and the full year 2026. Tyra Biosciences, currently trading around $35, holds a consensus "Moderate Buy" rating from analysts with a target price of $42.33.
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.4% - Here's What Happened
Tyra Biosciences (NASDAQ:TYRA) shares dropped 6.4% in mid-day trading with significantly lower volume after missing quarterly EPS estimates. Despite the dip, analysts maintain a "Moderate Buy" consensus rating with an average price target of $42.33, alongside recent "Outperform" and "Overweight" initiations from several firms. Insider transactions show a director selling a portion of their holdings, while institutional investors have actively adjusted their stakes in the precision oncology firm.
Tyra Biosciences announces $126 million stock sale in block transaction
Tyra Biosciences announced it has agreed to sell 4 million shares of its common stock to a large investment management firm for $126 million. The transaction comes as the company's stock trades near its 52-week high, following a significant 222% gain over the past year. Analysts have maintained positive ratings with increased price targets, recognizing the potential of its lead drug, dabogratinib, particularly with the initiation of a Phase 2 trial for upper tract urothelial carcinoma.
Tyra Bioscience Raises $126 Million in Block Share Sale
Tyra Bioscience (TYRA) has recently completed a block share sale, issuing 4,000,000 common shares at $31.50 each to an investment management firm, raising $126 million in gross proceeds. This transaction strengthens the company's financial flexibility and capital access, utilizing its existing at-the-market equity offering program. Despite a "Neutral" rating from TipRanks' AI Analyst Spark due to weak financial performance, the stock currently holds a "Buy" rating from analysts with an average price target of $42.00, supported by positive technical indicators.
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Tyra Biosciences has reached an agreement to privately issue 4 million common shares to a major investment management firm.
Tyra Biosciences, a biotechnology company, has agreed to privately issue 4 million common shares to a major investment management firm. This private placement, priced at $31.50 per share, was officially filed with the SEC and is expected to provide funding for the company's research and operations, indicating institutional investor confidence in its future prospects.
Tyra Biosciences agreed to issue 4 million shares at $31.50 per share to a large investment management firm - SEC filing
Tyra Biosciences has agreed to issue 4 million shares at a price of $31.50 per share to a major investment management firm, as disclosed in an SEC filing. This transaction indicates a significant private placement of shares by the biotechnology company. The news follows recent reports of the company's Q4 loss widening and various analyst price target adjustments.
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead
Tyra Biosciences' oral drug Dabogratinib is targeting blockbuster potential with pivotal studies and key data readouts expected this year in three major indications: UTUC, NMIBC, and achondroplasia. The drug's oral formulation, strong safety profile, and the high unmet medical need in these areas position it for rapid adoption, especially within community practices. This information is based on an AI-generated summary of Tyra Biosciences, Inc. [TYRA] TD Cowen 46th Annual Health Care Conference Audio Transcript from March 4, 2026.
